The FDA has extended approval of risankizumab-rzaa to include treatment of children down to age 6 years with active psoriatic arthritis (PsA) or those with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to a press release from the manufacturer. Risankizumab (SKYRIZI), an interleukin (IL) 23 inhibitor, was approved for treating moderate-to-sev...